Today: 21 May 2026
Ondas (ONDS) stock slips after $1 billion deal closes as traders eye dilution and Jan. 16 Investor Day
14 January 2026
2 mins read

Ondas (ONDS) stock slips after $1 billion deal closes as traders eye dilution and Jan. 16 Investor Day

New York, Jan 14, 2026, 12:48 (EST) — Regular session

  • Ondas shares dropped roughly 5% after the company sealed a $1 billion stock-and-warrant financing deal.
  • The deal brought in roughly $959 million in net proceeds but also introduced a sizable warrant overhang
  • This week saw the debut of a new 2x leveraged ETF linked to Ondas’ daily performance

Shares of Ondas Holdings Inc slipped roughly 5% on Wednesday, dragging on recent volatility following the company’s $1 billion stock-and-warrant offering. The stock dropped 5.3% to $13.16, fluctuating between $12.92 and $14.10, on volume of around 48 million shares.

Investors are fixated on the size of the raise. Ondas nets about $959 million in fresh proceeds, cash that could fuel acquisitions and growth. But the deal also balloons the potential share count with warrants that could weigh on trading for years.

The company reported selling 19 million common shares along with “pre-funded” warrants for up to 41.79 million shares to one institutional investor. Each warrant was paired with an option to buy two additional shares. These pre-funded warrants work similarly to shares, requiring most of the payment upfront, with only a small exercise price due later. Ondas Holdings Inc.

Ondas sold 60.79 million common stock equivalents and issued warrants for 121.58 million shares. The warrants carry a strike price of $28 per share and will remain valid for seven years, the company said. If those warrants are exercised for cash, Ondas could pull in roughly $3.4 billion more. However, the company emphasized there’s no guarantee this will occur.

Monday’s filing confirmed the registered direct offering has closed and included the press release as an exhibit. Registered direct offerings involve selling shares straight to investors under a registration statement already on file with the U.S. Securities and Exchange Commission.

Following the financing, Wall Street research acted fast. Stifel bumped its price target on Ondas from $13 to $17 and maintained a buy rating in a Monday note, MarketBeat reports.

Tradr ETFs rolled out a new 2x single-stock leveraged fund tied to Ondas on Tuesday. The Tradr 2X Long ONDS Daily ETF is set to debut on Cboe under the ticker ONDU. “This newest suite of funds touches on some hot button themes… namely drone technology and rare earth resources,” said Matt Markiewicz, head of product and capital markets at Tradr ETFs. PR Newswire

Leveraged single-stock ETFs target a multiple of a stock’s daily price change and reset every day. This setup can boost gains or losses quickly, but over time, returns often stray significantly from the stock itself, particularly when the shares fluctuate.

Ondas took center stage for investors this week. CEO Eric Brock is set for a fireside chat at the Needham Growth Conference on Wednesday morning and plans to conduct one-on-one meetings later in the day.

Ondas is gearing up to hold a virtual Investor Day on Jan. 16, where management will lay out an updated 2026 business plan, capital allocation strategy, and financial outlook. The event will wrap up with a Q&A session.

The risks remain clear. The stock faces a heavy overhang from pre-funded warrants and longer-dated common stock warrants, which could weigh on the shares if traders anticipate selling during rallies. If the price stays well under the $28 warrant strike, those touted “extra proceeds” might never materialize.

Investors are set to tune in Friday at 10:00 a.m. ET for Ondas’ Investor Day, eager for specifics on how the company intends to use its fresh capital. Market watchers will also be looking for any concrete updates from management on deal timelines, targets, or milestones set for 2026.

Stock Market Today

  • Sudarshan Colorants India's Earnings Show Potential Despite Profit Dip
    May 20, 2026, 8:53 PM EDT. Sudarshan Colorants India Limited (NSE:SUDARCOLOR) reported weaker profits last quarter, impacted by ₹50 million in unusual expenses that are unlikely to recur, suggesting potential profit rebound. The company's earnings per share (EPS) are growing strongly, indicating solid underlying business performance. Investors should consider balance sheet strength and monitor two identified warning signals, one considered significant. While profit was soft this time, analysts view Sudarshan Colorants' earnings outlook as cautiously optimistic, citing quality income statement elements and possible earnings improvements in the next quarter.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Erasca stock jumps 10% as Wall Street lifts targets to $11 on ERAS-0015 data
Previous Story

Erasca stock jumps 10% as Wall Street lifts targets to $11 on ERAS-0015 data

Intuit stock tumbles 7% as software selloff deepens; new $2.2 billion credit line in focus
Next Story

Intuit stock tumbles 7% as software selloff deepens; new $2.2 billion credit line in focus

Go toTop